Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib in Advanced Hepatocellular Carcinoma
NCT00287222Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Feb 2006
- Primary completion
- Sep 2010
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and erlotinib in hepatocellular carcinoma (HCC), sponsored by University of Arkansas. Primary endpoint: Proportion of subjects that remain free of progression at the 27th week at 27 weeks. Started Feb 2006; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00287222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287222.